Europe — EMA
Magaldrato Doc (Magaldrate)
GNH USA supplies Magaldrato Doc (Magaldrate), a antacid for heartburn, dyspepsia and gastric hyperacidity. Request a quote for global supply worldwide.
Request sourcing
What is Magaldrate?
Magaldrate, the active ingredient in Magaldrato Doc, is an antacid presented as an oral tablet for oral use. It neutralizes excess stomach acid and is used to relieve symptoms such as heartburn, dyspepsia and acid indigestion in adults and children, and is available over the counter in many EU countries.
GNH USA supplies Magaldrato Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across European and global markets.
What is Magaldrate used for?
Magaldrate acts on gastric acidity and is indicated for several common gastrointestinal conditions.
- Heartburn: provides rapid relief of burning sensation by raising gastric pH. - Dyspepsia: eases upper abdominal discomfort and fullness after meals. - Acid indigestion: reduces the sour taste and discomfort caused by excess acid. - Gastric hyperacidity: helps maintain a balanced gastric environment in chronic acid over‑production.
What are the side effects of Magaldrate?
Magaldrate is generally well tolerated, but adverse reactions can occur.
Common Side Effects: - Constipation: mild to moderate difficulty in bowel movements. - Diarrhoea: loose stools, often transient. - Nausea: feeling of unease or upset stomach. - Flatulence: increased intestinal gas. - Metallic taste: temporary alteration in taste perception. - Abdominal discomfort: mild cramping or pain.
Serious or Rare Side Effects: - Electrolyte imbalance: especially in patients with renal impairment. - Severe constipation or intestinal blockage. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Metabolic alkalosis: rare over‑correction of acidity. - Hypermagnesemia: elevated magnesium levels in susceptible individuals. - Renal function deterioration: in patients with pre‑existing kidney disease.
What precautions apply to Magaldrate?
Before using Magaldrato Doc, consider the following safety measures.
- Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: unknown safety profile; exercise caution. - Renal impairment: monitor magnesium load and adjust use accordingly. - Drug interactions: antacids may affect absorption of other oral medications; separate dosing times. - Pediatric use: administer only under medical supervision and appropriate dosing. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.
What does Magaldrate interact with?
Magaldrate can affect the absorption and efficacy of several medicines.
Major Interactions (Avoid): - Tetracycline antibiotics: reduced absorption leading to therapeutic failure. - Fluoroquinolone antibiotics: decreased bioavailability. - Iron supplements: diminished iron uptake. - Digoxin: possible increase in serum concentration.
Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Lithium: risk of increased lithium levels. - Beta‑blockers: may reduce absorption and efficacy.



